You are here

  • Home
  • Archive
  • Volume 7, Issue 1
  • Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial

Article metrics

Article menu

Download PDFPDF

XML
Research Article
Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial

 

Online download statistics by month:

Online download statistics by month: January 2020 to August 2025

AbstractFullPdf
Jan 202010100
Feb 202070700
Mar 202087877
Apr 202056565
May 202073733
Jun 202054545
Jul 202034344
Aug 2020484827
Sep 2020504915
Oct 2020303017
Nov 202024249
Dec 2020373522
Jan 2021646438
Feb 2021555535
Mar 202180809
Apr 202162626
May 202158587
Jun 202160607
Jul 202157575
Aug 202149498
Sep 202151514
Oct 2021737326
Nov 2021323218
Dec 202121216
Jan 202224252
Feb 2022202015
Mar 202214145
Apr 2022464910
May 2022161713
Jun 2022242410
Jul 2022192013
Aug 2022262612
Sep 202218189
Oct 202214148
Nov 202225259
Dec 202218184
Jan 2023272711
Feb 2023222415
Mar 202332338
Apr 202381111
May 202313137
Jun 202311113
Jul 2023121210
Aug 202317174
Sep 202326263
Oct 202333339
Nov 202312124
Dec 202314148
Jan 202427289
Feb 2024885
Mar 202415179
Apr 2024282816
May 202424256
Jun 202423239
Jul 2024303011
Aug 2024151616
Sep 202419199
Oct 2024464621
Nov 202423247
Dec 2024333314
Jan 2025222314
Feb 20259103
Mar 202518189
Apr 202530347
May 2025192022
Jun 2025202014
Aug 2025100
Total21362157687